Landmark Research Studies
completed

The objective of the ORIGIN study was to evaluate the effects of lantus (insulin glargine) versus standard care, and of Omega-3 fatty acids versus placebo, in reducing cardiovascular morbidity and mortality in high-risk people with impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes mellitus.

Primary endpoint:

Composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and significant heart failure.

Secondary endpoints:

Decline in the ability to perform everyday activities (key secondary outcome); renal dysfunction (primary outcome: end stage renal disease requiring dialysis or transplantation or doubling of serum creatinine); total mortality. All primary and secondary endpoints are adjudicated.

Download Presentation PDF
Study Type

Interventional - Drug

Study Design

Randomized controlled trial

NO. of Countries

40

NO. of Sites

578

NO. of Participants

12612

Study Period

2003-2010

Sponsor

PHRI

HERTZEL GERSTEIN DISCUSSES THE FINDINGS OF THE ORIGIN STUDY

Back To Top